Talis Biomedical Corporation TLIS
2.84
0.00
0.00%
as of 1 Apr
- Market cap
- $46.3M
- P/E
- 0.0×
Follow TLIS
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '23 | Dec '23 | Mar '24 | Jun '24 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(64.53%) | (63.32%) | (68.60%) | (70.48%) | |
| (50.10%) | (46.98%) | (53.08%) | (52.13%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(89.41%) | (86.19%) | (90.34%) | (91.40%) | |
Average Days of Receivables |
0.83 | 8.55 | 2.21 | — | |
Free Cash Flow per Share |
(30.81) | (29.56) | (23.95) | (22.02) | |
Free Cash Flow |
(56.05) | (53.73) | (43.63) | (40.12) | |
Capital Expenditures |
(0.63) | (0.49) | (0.43) | 0.14 | |
Piotroski F-Score |
2.00 | 3.00 | 3.00 | — | |
| Other line items | |||||
Cash ROIC |
(32.69%) | (36.50%) | (34.01%) | (37.11%) | |
Accounts Receivable Turnover |
10.03 | 11.92 | 14.87 | — | |
Accounts Payable Turnover |
0.69 | 0.02 | 0.01 | 0.00 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | — | |
Average Days of Payables |
416.24 | 11,920.37 | 48,923.52 | 0.00 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,181.01% | 1,906.94% | 2,975.83% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
1,475.77% | 1,322.12% | 3,383.82% | 0.00% | |
Share Based Compensation of Revenue |
210.06% | 203.89% | 381.09% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.73 | 0.86 | 0.76 | 0.79 | |
Depreciation/Fixed assets |
1.24 | 0.25 | 0.53 | 1.82 | |
Capex/Depreciation |
(0.15) | (0.63) | (0.50) | 0.18 | |
Revenue per Share |
1.21 | 1.17 | 0.54 | 0.00 | |
Operating CF per Share |
(30.47) | (29.29) | (23.71) | (22.09) | |
Capex per Share |
(0.35) | (0.27) | (0.24) | 0.08 | |
Capex to Sales |
0.29 | 0.23 | 0.44 | 0.00 | |
Net Profit Margin |
(3,436.98%) | (2,905.67%) | (5,784.73%) | 0.00% |
Columns are period end dates